A study of Fermaglich and Miller (2023) evaluated trends in orphan drug designations and approvals after the Orphan Drug ...
Tools4BLS
Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses? – Healthcare Economist
Cost-effectiveness analyzes (CEA) aim to examine how new healthcare technologies impact health outcomes and costs throughout a patient's life. While it is ...
That is the title of a KFF article published last week. Results are based on KFF. 2024 Employer Health Benefits Survey. ...
An interesting study of Miquel Serra-Burriel et al. (2024) It examines the impact of genericisation on drug prices in ...
Today marks the second anniversary of the Inflation Reduction Act, and it's clear how much progress the Biden-Harris Administration has made since then. ...
Medicare drug price negotiation is here. Medicare's maximum fair prices (MFPs) result in discounts of between 38% and 79%. In fact, the actual discounts ...
I was diagnosed with leukemia in 2019. My leukemia is considered a more aggressive type, but I am very lucky that there are new medications that do ...
The good news: Drug shortages in 2023 have declined in the United States from their recent peak between 2010 and 2012. ...
Delays in drug approval cost pharmaceutical companies money. These costs include both lost sales and the additional cost if clinical trials need to last ...
Recently, the Inflation Reduction Act (IRA) is receiving a lot of attention, particularly for its provision that allows CMS to begin price negotiations for ...
